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Abstract: Limited data are available regarding the impact of smoking cessation after atrial fibril-
lation (AF) diagnosis on clinical outcomes. Using the Korean National Health Insurance Service
database, we included patients newly diagnosed with AF and categorized them into four groups as
follows: (i) never smokers, (ii) ex-smokers, (iii) smoking cessation after AF diagnosis (“quitters”),
and (iv) current smokers. The primary outcomes were incident ischemic stroke and all-cause death
during follow-up. Fatal ischemic stroke and death from cerebrovascular events were evaluated
as secondary outcomes. Among 97,637 patients (mean age, 61 years; mean CHA2DS2-VASc score,
2.3), 6.9% stopped smoking after AF diagnosis. The mean follow-up duration was 3.2 ± 2.0 years.
After multivariable adjustment, quitters had lower risks of ischemic stroke (hazard ratio (HR), 0.702;
95% confidence interval (CI), 0.595–0.827) and all-cause death (HR, 0.842; 95% CI, 0.748–0.948) than
current smokers. Quitters after AF diagnosis were associated with lower risks of fatal ischemic
stroke (HR, 0.454; 95% CI, 0.287–0.718) and death from cerebrovascular events (HR, 0.664; 95% CI,
0.465–0.949) compared with current smokers. Quitting smoking may reduce the risk of ischemic
stroke, the severity of ischemic stroke, and the incidence of cerebrovascular events in patients with
new-onset AF.
Keywords: smoking; atrial fibrillation; stroke; death
1. Introduction
Atrial fibrillation (AF) is the most commonly encountered cardiac arrhythmia in clinical
practice, with an increasing prevalence associated with aging of the population [1–3]. The risk
of AF is related to concomitant cardiovascular diseases and lifestyle, and the identification
and management of these risk factors is important for modifying the risk of AF and the
burden of AF-related complications.
Smoking is associated with more than a two-fold increased risk of AF, and quitters
showed a lower trend of incident AF compared with current smokers [4]. Although the risk
of AF increases, smoking also increases the risk of stroke in the general population [5,6].
Previous studies have also shown an association between smoking and an increased risk of
stroke and death in patients with AF [7,8].
AF per se increases the risk of stroke by 5-fold and the risk of all-cause death by
1.9-fold in men and by 1.5-fold in women [9,10], consistent with recent studies [3,11,12].
Stroke is the most common cause of death in patients with AF, and AF-related stroke is a
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considerable healthcare burden [12,13]. Thus, stroke prevention with oral anticoagulation
(OAC) therapy is a cornerstone of AF management [14–16], and the identification and
management of modifiable clinical risk factors is crucial for improving clinical outcomes in
patients with incident AF. However, there are limited data on changing lifestyle behaviors,
such as smoking cessation after AF diagnosis, on clinical outcomes. Based on the lack of
evidence, current guidelines largely underemphasize the importance of smoking cessation
in the management of patients with AF [14–16]. Therefore, we aimed to evaluate the
association between smoking cessation after newly diagnosed AF and the risk of ischemic
stroke and all-cause death.
2. Materials and Methods
We used the Korean National Health Insurance Service (NHIS) database to acquire the
data used in this study [17]. Approximately 50 million people (the entire Korean population)
are provided with mandatory health insurance coverage by the government. The Korean
NHIS database includes demographic information and information on medical expenses
of enrollees, diagnoses, examinations, prescription dispensing records, and procedures
for inpatient and outpatient services [17,18]. Diagnoses are coded using the International
Classification of Diseases, Tenth Revision, Clinical Modification codes. Furthermore, all
enrollees aged ≥40 years are recommended to undergo biannual health screening provided
by the Korean National Health Insurance Corporation. The health examination includes
anthropometric measurement, blood pressure, laboratory examination, chest X-ray, and a
self-reported questionnaire on health behavior, including smoking, alcohol consumption,
and physical activity. The participation rate was 75% in 2014 [18]. These data were linked
to the Korean NHIS database as a National Health Screening database. All data generated
and analyzed during the current study are available from the National Health Insurance
Data Sharing Service (accessed at http://nhiss.nhis.or.kr/bd/ab/bada000eng.do (accessed
on 1 April 2021)).
This study complied with the principles of the Declaration of Helsinki. This study
was exempt from review by the Institutional Review Board of Seoul National University
Hospital (E-2003-027-1106).
2.1. Study Design and Study Population
The study design and enrollment flow are presented in Figures 1 and 2. We identified
523,174 patients who were newly diagnosed with AF between 1 January 2010 and 31
December 2016. Patients who underwent health examinations both within 2 years prior
to AF diagnosis and within 2 years after AF diagnosis were included. Patients diagnosed
with valvular AF and those <20 years were excluded. Patients with missing value(s) in
health examination data were excluded. To enhance accuracy in the diagnosis of stroke as
a clinical outcome, we excluded patients with a history of stroke before the second health
examination. Detailed definitions of diagnoses, such as AF, valvular AF, and prior stroke,
are shown in Table S1 [2,17].
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Figure 1. Study design. AF: Atrial fibrillation.
Figure 2. Study enrollment flow. AF: Atrial fibrillation.
Study patients were categorized by smoking status and changes before and after AF
diagnosis (Figure 1). Smoking status was evaluated using a self-reported questionnaire
in the first and second health examinations [19–24]. In this self-reported questionnaire,
subjects chose one answer among “never smokers,” “ex-smokers”, and “current smokers”
and recorded the cumulative amount of their smoking as packs per year. Patients were
categorized into four groups based on two sequential questionnaires: never smokers, ex-
smokers, quitters after AF diagnosis, and current smokers. Never smokers were defined
as patients who had never smoked; ex-smokers were defined as patients who had quit
smoking before the first examination and who had sustained their nonsmoking status until
the second examination (namely, ex-smokers were those who stopped smoking at any time
point before their incident AF); quitters were defined as patients who were current smokers
in the first health examination but who quit smoking after AF diagnosis by the time of the
second examination; current smokers were defined as patients who were current smokers
in the second examination, regardless of smoking status in the first examination.
2.2. Covariates
Covariates included patients’ demographic data, comorbidities, medications, and
results of health examinations. Patient demographic data, comorbidities, and medications
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were obtained from the Korean NHIS database. Table S1 summarizes the definitions of the
comorbidities [2,17]. Comorbidities included hypertension, diabetes mellitus, dyslipidemia,
heart failure, prior myocardial infarction (MI), peripheral artery disease (PAD), chronic
kidney disease (CKD), chronic obstructive pulmonary disease (COPD), and cancer [2,25–27].
The CHA2DS2-VASc score for assessing stroke risk was calculated by combining covariate
information (Table S1) [28]. Baseline medications, including OACs (i.e., warfarin or direct
oral anticoagulants, DOACs), aspirin, P2Y12 inhibitors, and statins, were identified between
the date of AF diagnosis and the date of the second health examination. Baseline variables
such as body mass index, waist circumference, systolic and diastolic blood pressure, fasting
glucose, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein
cholesterol, and estimated glomerular filtration rate at the second health examination were
collected. Alcohol consumption was categorized as nondrinker, mild-to-moderate drinker
(>0 g/day to <30 g/day), and heavy drinker (≥30 g/day). Regular exercise was defined as
performing >30 min of moderate physical activity ≥5 times a week, or >20 min of strenuous
physical activity ≥5 times per week. Low income was defined as patients with an income
in the lower 20% of the entire Korean population of subjects supported by the Medical
Aid program.
2.3. Study Outcomes and Follow-Up
The date of the second health examination was defined as the index date (Figure 1).
Incident ischemic stroke and all-cause death were identified as the primary outcome events.
The ischemic stroke included all the etiologies of ischemic stroke, including embolic stroke.
The secondary outcome events were fatal ischemic stroke and death from cerebrovascular
events. The detailed definitions of the study outcomes are presented in Table S1 [17,29].
Patients were followed up from the index date until the occurrence of ischemic stroke,
death, or 31 December 2017, whichever came first (Figure 1).
2.4. Statistical Analysis
Baseline characteristics are presented as mean ± standard deviation for continuous
variables and as numbers (percentages) for categorical variables. To evaluate the signifi-
cance of the differences among groups categorized by smoking status, one-way analysis
of variance and the chi-square test were used. The incidence rates of ischemic stroke
and all-cause death were calculated by dividing the number of incident cases by the total
follow-up period and presented as per 1000 person-years. Hazard ratios (HRs) and 95%
confidence intervals (CIs) for ischemic stroke and all-cause death were analyzed using
the Cox proportional hazards model. The HR is an estimate of the ratio of the hazard
rate in the comparators versus the reference group [30]. The assumption of proportional
hazards regression is that HR is constant over time. Thus, the HR indicates the relative
likelihood of the occurrence of the clinical event in comparators versus reference group at
any given time point. First, we provided an unadjusted HR. Then, a multivariable-adjusted
proportional hazards model was applied; model 1 was adjusted for age and sex and model
2 was adjusted for age, sex, comorbidities including hypertension, diabetes mellitus, dys-
lipidemia, heart failure, prior MI, PAD, CKD, COPD, and cancer; baseline medications
including OACs, aspirin, P2Y12 inhibitor and statin, baseline body mass index, heavy
drinker, regular exercise, low income, and CHA2DS2-VASc score.
Models 1 and 2, which were adjusted sequentially based on a priori considerations
for baseline covariates, were also evaluated (Models 3 to 6). Model 3 included age, sex,
baseline body mass index, heavy drinking, regular exercise, low income, and CHA2DS2-
VASc score; model 4 included all variables in model 3 except CHA2DS2-VASc score and
added comorbidities including hypertension, diabetes mellitus, dyslipidemia, heart failure,
and prior MI and PAD; Model 5 included all variables in Model 4 and added CKD, COPD,
and cancer; Model 6 included all variables in model 5 and added CHA2DS2-VASc score.
Additionally, early rhythm control could affect the incidence of clinical outcomes [31],
and we evaluated and further adjusted for the use of antiarrhythmic drugs and those
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undergoing AF ablation. Obstructive sleep apnea could also affect the risk of ischemic
stroke [32]. We evaluated and further adjusted for the prevalence of obstructive sleep
apnea in this study.
HRs are presented with never smokers as the reference group (model 2) and also
presented with current smokers as the reference group (model 2*) to more intuitively
present the relative risk of each group compared with current smokers. To account for the
possible influence of the cumulative smoking amount, we stratified each smoking group
by smoking amount into 0–10, 10–20, 20–30, and ≥30 pack-years. The potential effect
modification by sex, age (<65 years, 65–74 years, and ≥75 years), patients’ underlying
stroke risk assessed by CHA2DS2-VASc score (<3 and ≥3), and OAC treatment status
(non-OAC and OAC) were evaluated using subgroup analyses and interaction tests. p
for interaction <0.1 was considered the presence of significant interaction. Statistical
significance was set at p < 0.05. For statistical analyses, we used SAS version 9.4 (SAS
Institute, Cary, NC, USA).
3. Results
We included 97,637 patients in the analysis (mean age, 61.3 ± 12.3 years; men, 62.3%;
mean CHA2DS2-VASc score, 2.3 ± 1.5) (Figure 2). The mean time intervals between the
first health exam and AF diagnosis, between AF diagnosis and the second health exam,
and between the first and second health exams were 1.1 ± 0.5, 0.9 ± 0.5, and 2.0 ± 0.5
years, respectively. Of the study population, 51.2% were never smokers, 27.3% were ex-
smokers, 6.9% were quitters after AF diagnosis, and 14.6% were current smokers. The
baseline characteristics of the study population are presented in Table 1. Compared to
never smokers, the mean age and CHA2DS2-VASc score of ex-smokers, quitters after AF
diagnosis, and current smokers gradually became younger and lower, respectively. The
prevalence of comorbidities, including hypertension, diabetes, heart failure, prior MI,
COPD, and cancer, was higher in quitters after AF diagnosis than in the other groups.
Moreover, the rate of OAC treatment was slightly higher in quitters after AF diagnosis
than in the other groups. Heavy drinkers were more prevalent in current smokers than
in the other groups. Among all smokers, the total smoking (packs/year) was highest in
quitters after AF diagnosis, followed by current smokers and ex-smokers.
3.1. Primary Outcomes
3.1.1. Ischemic Stroke and All-Cause Death Stratified by Smoking Status
During a mean follow-up duration of 3.2 ± 2.0 years, a total of 3109 ischemic strokes
and 4882 all-cause death events occurred (10.0 per 1000 person-years and 15.4 per 1000
person-years, respectively). The crude event numbers, incidence rates, and HRs for is-
chemic stroke and death categorized by smoking status are presented in Table S2 and
Figure 3.
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(n = 14,212) p-Value
Age (years) 61.3 ± 12.3 63.1 ± 12.0 62.2 ± 11.2 57.8 ± 12.2 54.8 ± 12.4 <0.001
<65 years 54,735 (56.1) 24,667 (49.3) 14,538 (54.6) 4622 (68.3) 10,908 (76.8)
<0.00165 to <75 years 29,458 (30.2) 16,792 (33.6) 8472 (31.8) 1627 (24.0) 2567 (18.1)
≥75 years 13,444 (13.8) 8577 (17.1) 3611 (13.6) 519 (7.7) 737 (5.2)
Sex
Male 60,839 (62.3) 15,109 (30.2) 25,941 (97.5) 6337 (93.6) 13,452 (94.7) <0.001
CHA2DS2-VASc 2.33 ± 1.47 2.74 ± 1.5 2.02 ± 1.33 1.97 ± 1.34 1.65 ± 1.24 <0.001
0 7908 (8.1) 1809 (3.6) 2949 (11.1) 813 (12.0) 2337 (16.4)
<0.0011 24,061 (24.6) 9523 (19.0) 7466 (28.1) 1965 (29.0) 5107 (35.9)
≥2 65,668 (67.3) 38,704 (77.4) 16,206 (60.9) 3990 (59.0) 6768 (47.6)
Comorbidities
Hypertension 63,297 (64.8) 31,985 (63.9) 17,720 (66.6) 4611 (68.1) 8981 (63.2) <0.001
Diabetes mellitus 20,529 (21.0) 9785 (19.6) 5994 (22.5) 1617 (23.9) 3133 (22.0) <0.001
Dyslipidemia 10,512 (10.8) 5455 (10.9) 2514 (9.4) 783 (11.6) 1760 (12.4) <0.001
Heart failure 23,622 (24.2) 12,279 (24.5) 6433 (24.2) 1924 (28.4) 2986 (21.0) <0.001
Prior MI 4519 (4.6) 1992 (4.0) 1303 (4.9) 587 (8.7) 637 (4.5) <0.001
PAD 19,150 (19.6) 10,511 (21.0) 5035 (18.9) 1224 (18.1) 2380 (16.8) <0.001
CKD 12,779 (13.1) 7632 (15.3) 3261 (12.3) 797 (11.8) 1089 (7.7) <0.001
COPD 18,082 (18.5) 9225 (18.4) 4998 (18.8) 1564 (23.1) 2295 (16.2) <0.001
Cancer 5679 (5.8) 2900 (5.8) 1733 (6.5) 641 (9.5) 405 (2.9) <0.001
Medication
OAC 23,576 (24.2) 11,973 (23.9) 7039 (26.4) 1886 (27.9) 2678 (18.8) <0.001
Warfarin 17,341 (16.1) 7549 (15.1) 4694 (17.6) 1426 (21.1) 2002 (14.1) <0.001
DOAC 7905 (8.1) 4424 (8.8) 2345 (8.8) 460 (6.8) 676 (4.8) <0.001
Aspirin 20,482 (21.0) 10,091 (20.2) 6107 (22.9) 1409 (20.8) 2875 (20.2) <0.001
P2Y12 inhibitor 4965 (5.1) 2334 (4.7) 1480 (5.6) 501 (7.4) 650 (4.6) <0.001
Statin 15,664 (16.0) 8494 (17.0) 4151 (15.6) 1105 (16.3) 1914 (13.5) <0.001
Health exam parameter
BMI (kg/m2) 24.5 ± 3.3 24.5 ± 3.4 24.7 ± 3.1 24.7 ± 3.4 24.5 ± 3.4 <0.001
Waist circumference (cm) 84.4 ± 9.5 82.5 ± 10.1 86.6 ± 8.2 86.4 ± 8.8 85.7 ± 8.7 <0.001
Systolic BP (mmHg) 125.2 ± 15.3 125.3 ± 15.8 125.7 ± 14.6 124.7 ± 15.1 123.9 ± 14.6 <0.001
Diastolic BP (mmHg) 77.0 ± 10.2 76.6 ± 10.3 77.5 ± 10.1 77.3 ± 10.2 77.5 ± 10.2 <0.001
Fasting glucose (mg/dL) 104.4 ± 26.7 102.9 ± 25.5 105.5 ± 25.3 106.5 ± 29.4 106.4 ± 31.2 <0.001
Total cholesterol (mg/dL) 183.8 ± 41.0 186.1 ± 41.3 179.5 ± 40.0 182.3 ± 41.5 184.7 ± 41.1 <0.001
LDL-C (mg/dL) 105.5 ± 41.7 107.8 ± 41.7 102.7 ± 40.7 103.0 ± 38.5 103.7 ± 44.3 <0.001
HDL-C (mg/dL) 52.5 ± 15.2 54.0 ± 15.3 51.2 ± 15.8 50.5 ± 13.2 50.5 ± 14.4 <0.001
eGFR (mL/min/1.73 m2) 81.6 ± 28.0 80.6 ± 27.6 80.5 ± 27.5 82.7 ± 32.1 86.3 ± 27.9 <0.001
Smoking amount
(pack-years) 10.0 ± 15.8 0 19.1 ± 17.4 24.0 ± 19.1 21.4 ± 15.4 <0.001
0 (never smoker) 50,036 (51.3) 50,036 (100) 0 (0) 0 (0) 0 (0)
<0.001
>0 to <10 pack-years 12,648 (13.0) 0 (0) 8144 (30.6) 1443 (21.3) 3061 (21.5)
10 to <20 pack-years 12,510 (12.8) 0 (0) 6990 (26.3) 1583 (23.4) 3937 (27.7)
20 to <30 pack-years 9181 (9.4) 0 (0) 4863 (18.3) 1301 (19.2) 3017 (21.2)
≥30 pack-years 13,262 (13.6) 0 (0) 6624 (24.9) 2441 (36.1) 4197 (29.5)
Alcohol consumption
Nondrinker 62,450 (64.0) 40,945 (81.8) 13,194 (49.6) 3592 (53.1) 4719 (33.2)
<0.001Mild-to-moderate drinker 28,931 (29.6) 8223 (16.4) 11,005 (41.3) 2562 (37.9) 7141 (50.3)
Heavy drinker 6256 (6.4) 868 (1.7) 2422 (9.1) 614 (9.1) 2352 (16.6)
Regular exercise 21,903 (22.4) 9893 (19.8) 7667 (28.8) 1542 (22.8) 2801 (19.7) <0.001
Low income 16,279 (16.7) 8744 (17.5) 4000 (15.0) 1114 (16.5) 2421 (17.0) <0.001
Abbreviations: BMI, body mass index; BP, blood pressure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease;
DOAC, direct oral anticoagulant; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-
density lipoprotein cholesterol; MI, myocardial infarction; OAC, oral anticoagulant; PAD, peripheral artery disease.
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In multivariable analyses (model 2), ex-smokers were not found to have a higher risk
of ischemic stroke compared with never smokers. Smoking cessation after AF diagnosis
(quitters after AF diagnosis) and current smokers had a higher risk of ischemic stroke
than never smokers (quitters: HR, 1.191; 95% CI, 1.014–1.398; p = 0.032; current smokers:
HR, 1.697; 95% CI, 1.502–1.917; p < 0.001). With current smokers as the reference, quitters
after AF diagnosis had a significantly lower risk of ischemic stroke (HR, 0.702; 95% CI,
0.595–0.827; p < 0.001). Never smokers and ex-smokers also had lower risks of ischemic
stroke than current smokers (never smokers: HR, 0.589; 95% CI, 0.522–0.666; p < 0.001;
ex-smoker: HR, 0.602; 95% CI, 0.537–0.675; p < 0.001) (Figure 3).
For all-cause death, compared to never smokers, smokers were associated with a
higher risk of all-cause death with different impacts. The risk of all-cause death was higher
in ex-smokers (HR, 1.112; 95% CI, 1.024–1.207; p = 0.011), quitters after AF diagnosis (HR,
1.455; 95% CI, 1.300–1.629; p < 0.001), and current smokers (HR, 1.727; 95% CI, 1.569–1.902;
p < 0.001). With current smokers as the reference, quitters after AF diagnosis had a lower
risk of all-cause death (HR, 0.842; 95% CI, 0.748–0.948; p = 0.005). Never smokers and
ex-smokers also had a lower risk of all-cause death than current smokers (never smokers:
HR, 0.579; 95% CI, 0.526–0.638; p < 0.001; ex-smoker: HR, 0.644; 95% CI, 0.589–0.704;
p < 0.001) (Figure 3).
Figure 3. Hazard ratios of smoking status on the risk of ischemic stroke and all-cause death. * With current smokers as the
reference group; IR, per 1000 person-years. Abbreviation: CI, confidence interval; HR, hazard ratio; IR, incidence rate.
Results were consistent in different multivariable adjustment models (Figure S1).
When we additionally adjusted for the use of antiarrhythmic drugs and those undergoing
AF ablation, the results remained consistent (Tables S3 and S4). After adjusting for the
presence of obstructive sleep apnea, the results remained consistent (Tables S5 and S6).
3.1.2. Subgroup Analyses by Sex, Age, and CHA2DS2-VASc Score
In the subgroup analysis by sex, the results were consistent with the main results in
men (Figure S2). With current smokers as the reference, quitters after AF diagnosis had a
significantly lower risk of ischemic stroke (HR, 0.677; 95% CI, 0.569–0.806; p < 0.001) and
all-cause death (HR, 0.869; 95% CI, 0.768–0.082; p = 0.023) (Figure S2, panel A). In women,
although each smoker group category (except for never smokers) included a relatively
small number of patients, quitters after AF diagnosis and ex-smokers showed no significant
difference in the risk of ischemic stroke compared to current smokers (Figure S2, A panel).
For all-cause death, the results were consistent with the main results (Figure S2, B panel).
The p-values for the interaction between sex and the impact of smoking status on the risk
of ischemic stroke and all-cause death were 0.102 and 0.016, respectively.
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In the subgroup analysis by age group (<65 years, 65–74 years, and ≥75 years), al-
though the overall results were consistent with the main results, the p-values for interaction
between the age subgroups and the impact of smoking status on the risk of ischemic stroke
and all-cause death were both <0.001 (Figure S3, A panel). In patients aged 65–74 years,
quitters after AF diagnosis had a significantly lower risk of ischemic stroke than current
smokers (HR, 0.546; 95% CI, 0.411–0.725; p < 0.001), whereas the other age subgroups did
not show a significantly lower risk in the quitter after AF diagnosis group.
The impact of quitting smoking compared with current smoking was slightly more
attenuated in patients with a CHA2DS2-VASc score ≥3 (HR, 0.769; 95% CI, 0.605–0.979)
than in those with a CHA2DS2-VASc score <3 (HR, 0.649; 95% CI, 0.515–0.816) (Figure S3,
B panel). The trends of the impact of smoking status on the risk of ischemic stroke and
all-cause death were consistent in both the CHA2DS2-VASc subgroups and the main results.
A significant interaction was observed in both ischemic stroke (p = 0.027) and all-cause
death (p < 0.001) because of the difference in impact size.
3.1.3. Impact of Smoking Amount on the Risk of Ischemic Stroke and All-Cause Death
When stratifying each smoker group by smoking amount (0–10, 10–20, 20–30, and ≥30
pack-years), ex-smokers were not found to have a higher risk of ischemic stroke compared
with never smokers. In contrast, current smokers were consistently associated with a higher
risk of ischemic stroke compared with never smokers (Table 2). Among quitters after AF
diagnosis, patients with <30 packs per year were not associated with a higher risk of
ischemic stroke compared with never smokers. Quitters after AF diagnosis with ≥30 packs
per year had a higher risk of ischemic stroke compared with never smokers; however,
the HR was lower than that of current smokers, regardless of the smoking amount. For
all-cause death, ex-smokers with <30 packs per year were not associated with an increased
risk of all-cause death compared with never smokers. Quitters after AF diagnosis and
current smokers had a higher risk of all-cause death than never smokers; generally, the
HRs of current smokers were higher than those of quitters after AF diagnosis, regardless of
smoking amount.
3.2. Secondary Outcomes: Fatal Ischemic Stroke and Death from Cerebrovascular Events Stratified
by Smoking Status
Among the four groups, current smokers had a higher risk of fatal ischemic stroke
and death from cerebrovascular events than the other groups (Figure 4). Quitters after
AF diagnosis also had a significantly lower risk of fatal ischemic stroke (HR, 0.454; 95%
CI, 0.287–0.718) and death from cerebrovascular events (HR, 0.664; 95% CI, 0.465–0.949)
compared with current smokers (Figure 4).
3.3. Clinical Outcomes in Different Smoking Status According to the OAC Treatment
In the subgroup without OAC treatment, the results were consistent with the main
results (Figure 5). Although the risk reduction of each clinical outcome was slightly
attenuated in the subgroup with OAC treatment, there were no significant interactions
between the impact of smoking status on the clinical outcomes and the subgroups when
stratified by OAC treatment (Figure 5).
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Table 2. Hazard ratios of ischemic stroke and all-cause death in each group stratified by the smoking amount.







Ischemic stroke <0.001 <0.001 <0.001
Never smoker 0 50,036 1607 10.0 1 (reference) 1 (reference) 1 (reference)
Ex-smoker >0 to <10 8144 198 7.8 0.775 (0.668–0.898) 0.946 (0.805–1.111) 0.957(0.815–1.125)
≥10 to <20 6990 177 8.2 0.812 (0.695–0.948) 0.947 (0.799–1.122) 0.943 (0.795–1.117)
≥20 to <30 4863 149 9.9 0.979 (0.828–1.158) 1.032 (0.861–1.237) 1.038 (0.865–1.244)
≥30 6624 271 13.5 1.335 (1.174–1.519) 1.152 (0.995–1.333) 1.138 (0.982–1.318)
Quitter >0 to <10 1443 32 6.8 0.679 (0.479–0.963) 1.164 (0.817–1.657) 1.133 (0.795–1.613)
≥10 to <20 1583 36 7.1 0.703 (0.505–0.977) 1.107 (0.791–1.550) 1.069 (0.764–1.497)
≥20 to <30 1301 34 8.2 0.817 (0.582–1.147) 1.135 (0.803–1.604) 1.087 (0.768–1.537)
≥30 2441 98 12.5 1.247 (1.017–1.529) 1.346 (1.085–1.669) 1.315 (1.059–1.633)
Current smoker >0 to <10 3061 90 9.0 0.895 (0.724–1.107) 1.782 (1.429–2.221) 1.745 (1.399–2.177)
≥10 to <20 3937 125 10.0 0.994 (0.829–1.193) 1.802 (1.484–2.190) 1.763 (1.451–2.144)
≥20 to <30 3017 114 11.8 1.173 (0.970–1.418) 1.806 (1.475–2.211) 1.740 (1.419–2.133)
≥30 4197 178 13.1 1.302 (1.116–1.520) 1.667 (1.407–1.976) 1.609 (1.354–1.912)
All-cause death <0.001 <0.001 <0.001
Never smoker 0 50,036 2201 13.5 1 (reference) 1 (reference) 1 (reference)
Ex-smoker >0 to <10 8144 314 12.2 0.906 (0.805–1.020) 0.954 (0.840–1.084) 0.946 (0.833–1.074)
≥10 to <20 6990 312 14.2 1.055 (0.937–1.188) 1.054 (0.927–1.199) 1.050 (0.923–1.193)
≥20 to <30 4863 262 17.0 1.263 (1.111–1.435) 1.099 (0.958–1.261) 1.098 (0.957–1.260)
≥30 6624 575 27.8 2.074 (1.892–2.273) 1.378 (1.242–1.530) 1.293 (1.164–1.436)
Quitter >0 to <10 1443 58 12.1 0.901 (0.695–1.170) 1.602 (1.232–2.084) 1.417 (1.089–1.842)
≥10 to <20 1583 85 16.4 1.221 (0.983–1.517) 1.943 (1.557–2.426) 1.592 (1.275–1.987)
≥20 to <30 1301 87 20.6 1.529 (1.234–1.895) 1.971 (1.583–2.455) 1.591 (1.277–1.983)
≥30 2441 210 26.2 1.946 (1.689–2.242) 1.814 (1.561–2.108) 1.377 (1.183–1.601)
Current smoker >0 to <10 3061 133 13.0 0.962 (0.807–1.146) 1.938 (1.619–2.320) 1.769 (1.477–2.118)
≥10 to <20 3937 171 13.4 0.992 (0.849–1.159) 1.828 (1.553–2.152) 1.640 (1.392–1.932)
≥20 to <30 3017 169 17.0 1.261 (1.078–1.474) 1.866 (1.583–2.199) 1.713 (1.453–2.021)
≥30 4197 305 21.7 1.607 (1.426–1.812) 1.942 (1.705–2.212) 1.782 (1.562–2.033)
IR, per 1000 person-years. Model 1: age- and sex-adjusted Model 2: age, sex, hypertension, diabetes mellitus, dyslipidemia, heart failure,
prior MI, PAD, CKD, COPD, cancer, BMI, heavy drinking, regular exercise, low income, use of OAC, use of antiplatelet agent, use of statin,
and CHA2DS2-VASc score. Abbreviations: BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease; COPD, chronic
obstructive pulmonary disease; HR, hazard ratio; IR, incidence rate; MI, myocardial infarction; OAC, oral anticoagulant; PAD, peripheral
artery disease.
Figure 4. Hazard ratios of smoking status on the risk of fatal ischemic stroke and fatal cerebrovascular event. * With current
smokers as the reference group. IR, per 1000 person-years. Abbreviation: CI, confidence interval; HR, hazard ratio; IR,
incidence rate.
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Figure 5. Hazard ratios of smoking status on the risk of ischemic stroke, fatal ischemic stroke, death from cerebrovascular
events, and all-cause death according to their OAC treatment status. * With current smokers as the reference group. IR, per
1000 person-years. Abbreviation: CI, confidence interval; HR, hazard ratio; IR, incidence rate; OAC, oral anticoagulation; p
int, p for interaction.
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4. Discussion
To the best of our knowledge, this is the first and largest study to report the clinical
impact of smoking status (and the change in the latter following AF diagnosis) on ischemic
stroke and death in patients with newly diagnosed AF. The main findings were as follows:
(i) a substantial proportion of patients who were newly diagnosed with AF remained as
current smokers even after their AF diagnosis (14.6%), whereas 6.9% of patients stopped
smoking after their AF diagnosis; (ii) current smoking was associated with the highest risk
of ischemic stroke and all-cause death; (iii) compared with current smokers, quitters after
AF diagnosis had a lower risk of ischemic stroke by 30% and all-cause death by 16%; (iv)
compared with current smokers, quitters had a significantly lower risk of fatal ischemic
stroke by 55% and death from cerebrovascular events by 34%. This suggests that the benefit
of risk reduction of all-cause death in quitters is mainly caused by the reduction in fatal
neurologic adverse events; (v) the benefit of smoking cessation after AF diagnoses on the
risk reduction of primary and secondary clinical outcomes was significant, irrespective of
the OAC treatment status.
Current guidelines have emphasized the importance of appropriate OAC treatment
according to patients’ risk profiles to reduce the risk of stroke and improve overall outcomes
in patients with AF [14–16]. The initial period after AF diagnosis is critical for three reasons.
First, the risk of clinical events in patients with AF appears to be especially higher than that
in patients without AF within the initial period after diagnosis [3]. In large observational
studies, the HR for ischemic stroke was 13.28 (95% CI, 10.89–16.20) within 6 months after
AF diagnosis and decreased after 6 months (HR, 3.31; 95% CI, 3.23–3.39) when compared to
non-AF patients in each period [3]. Second, risk assessment for stroke should be completed
to determine optimal OAC treatment [14–16]. Third, in the initial period of AF diagnosis,
motivating patients to adopt a healthy lifestyle can be more impactful and implementable
to patients. Although suggesting a healthy lifestyle to achieve better clinical outcomes is
an important part of primary prevention for patients with AF, current AF guidelines have
not emphasized this topic due to lack of evidence.
The implementation of adequate OAC therapy for stroke prevention, better control
of AF symptoms, and management of concomitant comorbidities and cardiovascular
risk factors are crucial for the optimal care of patients with AF. Among these, lifestyle
modification is part of the management of concomitant cardiovascular risk [33]. Although
there is some evidence of the clinical impact of lifestyle modifications in patients with
AF, modifying behavior is still underemphasized in recent guidelines. For example, in
the 2016 European Society of Cardiology Guidelines for AF management [34], there was
just one recommendation, as follows: “patient involvement in the care process should be
considered to encourage self-management and responsibility for lifestyle changes” (Class
IIA, Level of Evidence C). Although smoking is mentioned as a risk factor for stroke
in patients with AF in more recently updated guidelines, there have been no specific
recommendations for smoking. In contrast, other lifestyle modifications, such as weight
loss, blood pressure control, and alcohol reduction, are generally emphasized more in
the currently updated guidelines [15]. To educate and encourage smoking cessation in
patients who are newly diagnosed with AF, more data are needed to inform evidence-based
guideline recommendations. Based on the results of the present study, smoking cessation
should be added to the “to-do list” after AF diagnosis.
Previous studies have reported the impact of smoking status on cardiovascular out-
comes in patients with AF [7,8,35]. One clinical cohort trial suggested that smoking may
increase the risk of thromboembolic events in patients with anticoagulated AF by 2-fold [7].
Of note, smoking has not been included in stroke risk stratification schemes [14–16], and
one previous study failed to demonstrate that smoking was a significant and independent
risk factor for stroke in patients with AF [36]. In the Danish Diet, Cancer and Health cohort
study, which included 3161 patients with incident AF, smoking did not show a significant
increase in the risk of stroke in both men and women; however, this study did not include
an analysis of the impact of quitting smoking after AF diagnosis [8]. Another recent study
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evaluated the association between smoking habits and the incidence of cardiovascular
outcomes in patients with AF [35]. Although this study showed similar results to those of
the current study, our study has several additional strengths. First, we included a substan-
tially larger population cohort (97,637 vs. 2372), including women; thus, the conclusion
can be interpreted as being more generalizable. In addition, based on a much larger scale
study population, we were able to analyze the consistency of the main results in vari-
ous subgroups and to evaluate the dose–response relationship between smoking amount
and clinical outcomes. Second, the previous report evaluated various clinical outcomes,
including composite cardiovascular disease, stroke, coronary heart disease, and acute
MI, and the results showed significant reduction in the risk of composite cardiovascular
disease, total stroke, and ischemic stroke. In the present analysis, we focused more on
ischemic stroke and added all-cause death as a relevant hard endpoint (to access net clinical
benefit). To address the risk reduction of all-cause death in “quitters after AF diagnosis”
and the impact of quitting smoking on the severity of ischemic stroke, we added data
on fatal stroke events and deaths from cerebrovascular disease as secondary outcomes.
Based on previous studies, the clinical impact of smoking on the severity of stroke remains
controversial and has been reported to vary in different etiologies of stroke [37–39]. In
the present analysis, we demonstrate that not only was the risk of ischemic stroke lower,
but the risks of fatal ischemic stroke and death from cerebrovascular events were also
significantly lower in quitters after AF diagnosis than in current smokers. Third, the study
period differed between the two studies. The previous report by Choi et al. [35] analyzed
data from 2003 to 2012, when warfarin was the only option for OAC therapy and OAC
prescription was low (approximately 15% of the total population). In the present study, we
included patients from 2010 to 2016 with a much higher OAC treatment rate (approximately
25% of the total population), including 7905 patients treated with DOACs. The present
study therefore reflects a much more contemporary treatment pattern of OAC, which is
an important confounder when considering ischemic stroke. In the subgroup analysis by
OAC treatment status, the main results showing that quitters after AF diagnosis had lower
risks of clinical outcomes compared with current smokers were consistently observed in
both the non-OAC and OAC groups. Although the beneficial effect of quitting smoking
was slightly attenuated in the OAC groups, the importance of quitting smoking should
still be emphasized to all patients with AF, regardless of OAC treatment. Even though we
included a larger number of patients treated with DOAC than in previous studies [8,35],
warfarin was still mainly used in this study population. The proportion of DOAC use
was limited. Therefore, the impact of wider use of DOAC, as currently observed in many
countries, is unknown.
In the general population, smoking is a well-established risk factor associated with
an increased risk of stroke [6,40]. In addition, the Framingham study demonstrated that
quitting cigarette smoking led to a lower risk of stroke compared with continued smoking,
but there was no significant difference between quitters and nonsmokers with regard to
stroke risk [6]. The quitting effect occurred quite soon after smoking cessation, and the risk
of stroke had decreased significantly 2 years after quitting and became similar to that of
nonsmokers within 5 years of quitting [6].
Our study showed results consistent with those of a previous population-based
study among patients with AF. Quitters after AF diagnosis showed a higher prevalence of
comorbidities than that of other groups at the baseline. There is the possibility that more
proactive lifestyle modification might be implemented in so-called “sicker patients” at
baseline. After adequately adjusting for differences in the baseline characteristics, quitters
after AF diagnosis were significantly associated with lower risks of ischemic stroke, all-
cause death, fatal ischemic stroke, and death from cerebrovascular disease. The rapid
risk reduction after quitting smoking can be explained by the possible mechanisms by
which smoking precipitates thromboembolic events by increasing serum fibrinogen levels,
promoting a hypercoagulable state, and causing platelet dysfunction [41–45]. Although
increased thrombogenicity is associated with an increased risk of stroke in current smokers,
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as in the general population, there is limited evidence of the role of AF in the risk reduction
of ischemic stroke after smoking cessation. The effect of aggressive risk factor reduction,
including smoking cessation after AF ablation, has been reported [46]. In this previous
observational study, aggressive risk factor management reduced AF recurrence after AF
ablation. Lifestyle factors may be the primary promoters of AF substrates to facilitate
rhythm control strategies; however, this previous study included a relatively small number
of patients and elucidated the effect of the “cluster” of risk factor management rather
than each individual risk factor. Further investigation is therefore needed to explain the
mechanism of stroke risk reduction after smoking cessation, especially the role of the
AF burden.
Unfortunately, this study did not include a detailed etiology of ischemic stroke given
the inherent limitations of the database, which lacks detailed results of brain imaging
studies. Although it is well known that cardiogenic embolism is a common cause of
ischemic stroke in patients with AF, other subtypes of ischemic stroke are also responsible
for a substantial proportion of strokes in patients with AF [47–49]. In addition, patients
with higher CHA2DS2-VASc scores have a higher chance of having more risk factors for
both cardioembolic and non-cardioembolic ischemic stroke [50]. Hence, to reduce the
overall ischemic stroke risk burden in patients with AF, a general reduction in overall
cardiovascular risk is also necessary. The remaining risk after smoking cessation might be
mediated by atherosclerosis, which will impact long-term outcomes, particularly the risk
of all-cause mortality [51,52]. Of note, smoking cessation was favorable for the ischemic
stroke outcome in patients with a substantial cumulative smoking amount, but the benefit
was attenuated in prior heavy smokers (≥30 pack-years) among quitters after AF diagnosis
(Table 2). The attenuation of benefit in prior heavy smokers could be related to long-term
vascular and endothelial damage associated with atherothrombosis.
We observed several interactions between different subgroups and the impact of
smoking status on the risk of ischemic stroke and all-cause death. However, the statistical
power was affected by the total number of patients and the incidence rate of clinical
outcomes in each subgroup. Although the benefit of quitters after AF diagnosis was more
accentuated in a certain subgroup, such as men, patients aged 65–74 years, and those
with lower CHA2DS2-VASc scores, it is important to consider that the crude incidence
rates of ischemic stroke and all-cause death varied widely among the different subgroups.
In addition, the total number of certain subgroups was relatively smaller than in others
(e.g., women and patients aged ≥ 75 years). These factors should be considered when
interpreting the results of subgroup analyses. Despite the fact that the HRs were slightly
attenuated and the CI of quitters after AF diagnosis became wider in a certain subgroup, the
directionality of the HRs of quitters after AF diagnosis was consistent with the main results.
However, further studies on the impact of quitting smoking in the women subgroup or
patients at a lower risk of stroke are needed in the future.
Limitations
Our study has several limitations. First, this was an observational, retrospective
cohort study, and therefore, the relationship between smoking cessation and lower risks
of ischemic stroke and death is limited to association rather than causality. Considering
the ethical issues of the lifestyle modification study (e.g., randomizing cardiac patients to
keep smoking or stopping smoking), we assumed that randomized clinical trials could not
be performed to support this hypothesis. Second, although we considered and carefully
adjusted covariates that could affect the clinical outcomes, there is a possibility that con-
founding factors have remained. For the given variables, we applied a stepwise approach
to gradually adding clinical variables. The main results were consistently observed in
various multivariable adjustment models (Figure S1). Third, although this study included
a large population, only Asians from a single nationality were included, which should be
considered when generalizing the findings. Fourth, we excluded patients with a history
of stroke. Patients who experienced a stroke before AF diagnosis might have a greater
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burden of atherosclerotic disease than those who did not [53], and the self-motivation or
reinforcement for lifestyle modification (i.e., quitting smoking) by physicians might be
different. Fifth, the prescription of OACs was relatively low, but this has been consistently
observed in previous reports from Asian real-world practice [54,55]. More optimal OAC
therapy after a diagnosis of AF is necessary to reduce the risk of stroke. Despite these
limitations, we have analyzed the largest number of study populations to generate the per-
suasive main recommendation that smoking status should become an important lifestyle
factor to be routinely considered and addressed in the management of patients presenting
with the first episode of AF. Sixth, since the estimation of smoking habits was based on
the self-reported questionnaires, there might be a possibility of underestimating the true
prevalence of smoking. Although this study did not include the measurement of exhaled
carbon monoxide levels, it could be useful to evaluate actual smoking status [56]. Seventh,
there is a possibility that the dynamic changes of other lifestyle factors could affect the risk
of clinical outcomes. We adjusted for comorbidities, physical activity, body mass index,
and alcohol intake assessed at the second health examination (the latest status, namely, at
the starting point of clinical events follow-up) in the multivariable adjustment model. Since
the aim of the study was to evaluate the impact of smoking status changes on the risk of
ischemic stroke and all-cause death in patients with incident AF, we did not analyze the im-
pact of changes in several other lifestyle factors on the clinical outcomes. Eighth, although
the type, the burden, or the recurrence of AF could affect clinical outcomes, we did not have
detailed information on these factors given the inherent limitations of the database. Further
studies are needed on the type or burden of AF, which would be a possible mediator for
the increased risk of ischemic stroke and all-cause death in current smokers. Lastly, we
only focused on patients with AF in this study, because these patients have a higher risk
of stroke. In patients with AF, the etiology is more likely to be cardioembolic stroke, and
the risk of cardiovascular and all-cause death is also much higher [12]. In a recent report
from our group, even among AF patients at low risk of stroke (CHA2DS2-VASc score 0 in
men or 1 in women), current smoking was the only independent and significant factor for
predicting ischemic stroke due to cardioembolic mechanisms [57]. Therefore, we believe
that it is worthwhile and necessary to evaluate the risk of smoking on stroke and the
beneficial effects of quitting smoking on reducing stroke risk in special populations such as
patients with AF. The results of this study could provide evidence for holistic management,
including lifestyle modification beyond medical therapy alone for patients with AF.
5. Conclusions
Smoking cessation after incident AF was associated with a lower risk of ischemic
stroke and all-cause death compared with current smoking. Lifestyle changes, such as
quitting smoking after a diagnosis of AF, may reduce the risk of ischemic stroke and reduce
the severity of ischemic stroke and cerebrovascular events in patients with new-onset AF.
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